Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.

Squires MS, Feltell RE, Wallis NG, Lewis EJ, Smith DM, Cross DM, Lyons JF, Thompson NT.

Mol Cancer Ther. 2009 Feb;8(2):324-32. doi: 10.1158/1535-7163.MCT-08-0890. Epub 2009 Jan 27.

2.

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.

Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S, Cirstea D, Pozzi S, Mitsiades C, Rooney M, Kiziltepe T, Podar K, Okawa Y, Ikeda H, Carrasco R, Richardson PG, Chauhan D, Munshi NC, Sharma S, Parikh H, Chabner B, Scadden D, Anderson KC.

Leukemia. 2009 May;23(5):961-70. doi: 10.1038/leu.2008.378. Epub 2009 Jan 8.

PMID:
19151776
3.

Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.

Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML.

Nature. 2008 Oct 30;455(7217):1205-9. doi: 10.1038/nature07284. Epub 2008 Sep 17.

4.

Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids.

Venè R, Larghero P, Arena G, Sporn MB, Albini A, Tosetti F.

Cancer Res. 2008 Sep 1;68(17):6987-96. doi: 10.1158/0008-5472.CAN-07-6362.

5.

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.

Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA, Carr MG, Cross DM, Davis DJ, Devine LA, Early TR, Feltell RE, Lewis EJ, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Reule M, Saxty G, Seavers LC, Smith DM, Squires MS, Trewartha G, Walker MT, Woolford AJ.

J Med Chem. 2008 Aug 28;51(16):4986-99. doi: 10.1021/jm800382h. Epub 2008 Jul 26.

PMID:
18656911
6.

Progress in the evaluation of CDK inhibitors as anti-tumor agents.

McInnes C.

Drug Discov Today. 2008 Oct;13(19-20):875-81. doi: 10.1016/j.drudis.2008.06.012. Epub 2008 Aug 3. Review.

PMID:
18639646
7.

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, Vanderkerken K, Chen-Kiang S.

Cancer Res. 2008 Jul 15;68(14):5519-23. doi: 10.1158/0008-5472.CAN-07-6404.

8.

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

Neri A, Marmiroli S, Tassone P, Lombardi L, Nobili L, Verdelli D, Civallero M, Cosenza M, Bertacchini J, Federico M, De Pol A, Deliliers GL, Sacchi S.

Leuk Lymphoma. 2008 Jul;49(7):1374-83. doi: 10.1080/10428190802078289.

PMID:
18452078
9.

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.

Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC.

Br J Haematol. 2007 Sep;138(6):783-91.

PMID:
17760810
10.
11.
12.

IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes.

Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, Takemura T, Suzuki K, Kitagawa M.

Am J Hematol. 2006 Nov;81(11):824-31.

13.

Cyclin-dependent kinase pathways as targets for cancer treatment.

Shapiro GI.

J Clin Oncol. 2006 Apr 10;24(11):1770-83. Review.

PMID:
16603719
14.

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.

Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane J, Chen-Kiang S.

Cancer Res. 2005 Dec 15;65(24):11345-53.

15.

Molecular pathogenesis and a consequent classification of multiple myeloma.

Bergsagel PL, Kuehl WM.

J Clin Oncol. 2005 Sep 10;23(26):6333-8. Review.

PMID:
16155016
16.

Cyclins and CDKS in development and cancer: lessons from genetically modified mice.

Santamaria D, Ortega S.

Front Biosci. 2006 Jan 1;11:1164-88. Review.

PMID:
16146805
17.

Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation.

Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T.

Biochem Biophys Res Commun. 2005 Sep 9;334(4):1365-73.

PMID:
16043125
18.

Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

Chen R, Keating MJ, Gandhi V, Plunkett W.

Blood. 2005 Oct 1;106(7):2513-9. Epub 2005 Jun 21.

19.

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.

MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR.

Cancer Res. 2005 Jun 15;65(12):5399-407.

20.

Role of CDK/cyclin complexes in transcription and RNA splicing.

Loyer P, Trembley JH, Katona R, Kidd VJ, Lahti JM.

Cell Signal. 2005 Sep;17(9):1033-51. Review.

PMID:
15935619

Supplemental Content

Support Center